Immunotherapy for Pemphigus: Present and Future

Frontiers in Medicine

article

Huijie Yuan¹  Meng Pan²  Hongxiang Chen¹  Xuming Mao⁴ 

[1]Department of Dermatology, Huazhong University of Science and Technology Union Shenzhen Hospital

[2]Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

[3]Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

[4]Department of Dermatology, University of Pennsylvania

关键词: pemphigus;    improved efficacy;    immunotarget;    novel therapy;    clinical trial;   

DOI  :  10.3389/fmed.2022.901239

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Pemphigus is a chronic and severe autoimmune bullous disease caused by autoantibodies targeting adhesion molecules between keratinocytes. It requires 2–3 years on average to manage the disease. To date, although Rituximab combined with short-term systemic glucocorticoids was accepted as first-line therapy, systemic glucocorticoids remain the primary therapeutic option for pemphigus patients, successfully decreasing morbidity and mortality from pemphigus. However, novel therapeutic strategies are desirable due to the low efficacy in some subset of patients and the long-term severe adverse effects of traditional therapies. Recently, immunotherapy has proved to be encouraging for disease control or cure. Based on the current understanding of the immune mechanisms of pemphigus, we review the immune targets and corresponding agents applied in practice or under clinical trials. The goals of the novel treatments are to improve the quality of life of pemphigus patients by improving efficacy and safety, minimizing side effects, achieving fast disease control, or curing the disease.

【 授权许可】

CC BY